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Abstract
Hydrophilic polymers are ubiquitously applied as surface coatings on catheters and intravascular 
medical technologies. Recent clinical literature has heightened awareness on the complication of 
hydrophilic polymer embolism (HPE), the phenomenon wherein polymer coating layers separate 
from catheter and device surfaces, and may be affiliated with a range of unanticipated adverse 
reactions. Significant system barriers have limited and delayed reporting on this iatrogenic 
complication, the full effects of which remain under-recognized by healthcare providers and 
manufacturers of various branded devices. In 2015, the United States Food and Drug 
Administration acknowledged rising clinical concerns and stated that the agency would work with 
stakeholders to further evaluate gaps that exist in current national and international device 
standards for coated intravascular medical technologies. The present article reviews current 
knowledge on this complication as well as factors that played a role in delaying detection and 
dissemination of information and new knowledge once hazards and clinical risks were identified. 
Furthermore, organ-specific effects and adverse reaction patterns are summarized, along with 
implications for device manufacturing, safety testing, and regulation. Particulate analyses and 
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general enhanced processes for device surveillance are needed to optimize vascular technologies 
and to ensure patient safety.
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Introduction
Hydrophilic polymers are ubiquitously applied as surface coatings on modern intravascular 
medical technologies. These include guidewires, introducer and delivery sheaths, 
implantable stents and coils as well as cardiac, central and peripheral catheters. Hydrophilic 
coatings such as polyvinylpyrrolidone (PVP), polyacrylamide (PAM), polyoxyethylene 
(PEG), polysaccharides and proprietary co-polymer blends imbibe water and expand when 
subjected to aqueous environments. These coatings were introduced in the 1980s following 
recognition of their unique capabilities in increasing lubricity, enhancing hemocompatibility, 
and enabling targeted intravascular drug delivery while improving drug compliance. With 
major trends toward minimally invasive techniques and novel drug delivery systems, 
applications of medical polymer device coatings continue to grow worldwide, with global 
demands predicted to net $11.8 billion by 2021 [1].
Despite trends and advancements in endovascular techniques and capabilities, significant 
adverse effects have been linked with coated device use in various postprocedural clinical 
settings [2-7]. Unanticipated biological reactions including delamination and degradation of 
device surface materials, with subsequent embolism of released coating particulates within 
the bloodstream, have increasingly been reported following routine intravascular device use. 
We first reported fatal complications to the United States Food and Drug Administration 
(FDA) in 2009 and hypothesized that morbidity and mortality due to iatrogenic hydrophilic 
polymer embolism (HPE) were clinically underrecognized [8,9]. In recent years, additional 
iatrogenic hydrophobic polymer coating reactions have been described, and accumulating 
adverse event reports over the past decade provide evidence that clinical complications from 
device coatings and particulates have not been fully realized.
A review on this topic reveals significant barriers and lags in investigating and reporting on 
medical HPE complications [10]. Furthermore, there were significant delays in 
dissemination of knowledge once new hazards and clinical risks were identified [11]. Today, 
three decades following the introduction of coated vascular medical devices for clinical 
applications, the full scope of HPE coating complications continues to be understated. 
Postmarket data on the subject are sparse in the published literature, although available 
information suggests clearly the need for further investigation and extensive quality 
improvement initiatives. The present article reviews current knowledge on HPE-related 
complications and summarizes organ-specific effects, along with implications for device 
manufacturing, safety testing, and regulation.
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Search Parameters and Materials Reviewed
In compiling this review, several sources of relevant literature and information were queried. 
Pubmed/MEDLINE was searched for reports published from 1986 to 2016, using the terms 
“hydrophilic polymer embolism”, “HPE” and “polymer coating emboli”. Pertinent citations 
and references from identified reports were extracted for further evaluation. Manuscripts 
with available histopathologic data, published in the English language, and unpublished 
cases and consults in our files with documented HPE were included in the analysis. United 
States FDA guidelines and communications, postmarket surveillance procedures, available 
manufacturer literature, medical device recalls and standards for vascular device clearance 
were additionally evaluated. Outcomes of previous manuscript submissions, including our 
experience in publishing on this subject over the past decade were assessed. Particulate size 
dimensions, adverse events, factors that delayed or prevented publication of HPE 
observations, and a timeline of publication and regulatory activities on the topic are 
summarized.
Limited Investigation and Subtle Histopathologic Appearances
In the absence of clinical suspicion for iatrogenic coating complications, and without 
targeted histopathologic analysis, HPE eluded clinical detection for many years (Fig. 1). 
Recognition of clinical HPE phenomena requires directed biopsy of vital tissues, thorough 
postmortem analysis of organs and vasculature, and/or evacuation of embolic or thrombus 
material for definitive histologic detection [3-5]. Declining hospital autopsy rates, lack of 
reimbursement for postmortem procedures and limited research funding and support in this 
area are additional factors that hindered documentation and reporting of iatrogenic HPE 
complications. While histologic analysis remains the only available methodology for 
definitive diagnosis, subtle microscopic appearances of intravascular polymer and 
limitations of tissue sampling led to frequent false negative interpretations and significant 
underreporting [4,5]. The non-polarizable and non-refractile histologic characteristics of this 
foreign material allowed it to be repeatedly overlooked by experienced pathologists as 
incidental findings or artifacts of tissue processing and staining. Fluctuating in vivo 
histologic appearances resulting from associated intravascular hydration, degradation and 
inflammation further shrouded diagnosis of many cases (40). Lack of available corroborative 
methodologies for determination of embolic degree also complicated extent of reporting. 
Furthermore, variable experience among diagnostic physicians precluded consensus 
guidelines for reporting. With expanded knowledge and gradual increase in recognition of 
predicted tissue appearances and effects, however, there has been a marked increase in HPE 
reporting over recent years (Fig. 1, Table 1) [2-44].
Reported Adverse Events, Contributory Devices and Incidence
Following localized access site deposition or embolism to distal organs, polymeric deposits 
measuring up to 1.9 mm in cross section and 2.3 cm in longitudinal section, have been 
shown to induce vasoocclusion, in most cases with associated intra- and/or peri-vascular 
inflammation, thrombus formation, and/or fibrosis (Fig 2, Table 2). Adverse reactions have 
been documented in patients aged 2 months to 89 years [43,44] and have involved the heart 
[5,19-21,24,27,29,33], lungs [4,5,10,28], brain [2,3,5,8,9,18,22,30,40,43], kidneys [21,23], 
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skin/subcutaneous tissues and extremities [12-17,25,26,31,32,44], arteriovenous and 
transplant grafts [9,21], colon [35], spinal cord [5], liver [7], spleen, pancreas, adrenal glands 
and muscle (Table 1), and on occasion have been associated with multisystem involvement, 
including multiple organ failure and/or systemic inflammatory response syndrome [5,7]. 
Recognized organ-specific reactions and clinical sequelae are summarized in Table 2. While 
reactions are often incidental or of unclear clinical significance, significant secondary 
reactions have been found to recur or persist in some patients for several years [7]. Factors 
impacting on clinical outcomes have been shown to include embolic number, embolic 
size(s), embolic morphologies, afflicted organ(s), site(s) of tissue or organ involvement, co-
existing patient morbidities and severity of secondary tissue reactions [5,7,40]. Symptomatic 
responses may be self-limiting, or alternatively, may lead to focal or multifocal parenchymal 
necrosis with potential disability due to symptomatic vital organ or limb infarction and/or 
patient death (Table 2). Due to multiplicity of clinical procedures and instruments used, 
causative devices have often been indiscernible on retrospective exams, despite the fact that 
a wide variety of procedures and device types were recognized to be contributory [5,9]. 
While hospital autopsy analyses have revealed postmortem HPE frequencies of 10-13% 
[5,33], clinical evidence from targeted in vivo investigations highlight incidences of up to 
45-86% in select populations [33,36,39].
Barriers to Investigating, Publishing and Reporting
Submitted manuscripts on this subject underwent rigorous review at multiple journals, with 
up to six reviewers per journal and mean total review time of 2 years per single manuscript 
[5,6,8-10]. Contradictory reviewer comments resulted in multiple rejections, and often 
included concerns that reports were not of clinical significance and that associated findings 
would have little or no impact on device manufacturing, user guidelines or regulation [11]. 
The majority opinion among cardiovascular interventional reviewers was that postmortem 
interpretations were of limited clinical relevance and that HPE were epiphenomena of 
intravascular device use. Additional editorial comments included statements that the subject 
matter was low priority for publication or was outside the desired scope of various clinical 
and subspecialty journals. Competing interests resulted in manufacturer hesitancy to disclose 
proprietary coating compositions and manufacturing processes, avoidance of reporting by 
treating physicians, mitigation of institutional reporting and liability by administrators and 
risk management; and limitations on resources and support for detailed diagnostic 
investigation and formal quality improvement initiatives. Other factors that hindered or 
precluded reporting included high physician clinical workloads; absence of standardized 
hospital adverse event reporting system(s); unclear procedure(s) and limited receptivity for 
near miss reporting; voluntary and open-ended nature of federal adverse event reporting 
forms; lack of interdisciplinary communication; lack of institutional cooperation in patient 
and device reporting; absence of available preclearance or postmarket data and device 
information for corroboration of new findings; absence of feedback and transparency during 
formal reporting processes; lack of clarity and awareness regarding which physician or 
system member should report; general lack of support and network for young female and 
minority investigators; and editorial rejection of additional case encounters due to stated lack 
of “novel findings”. Factors impacting on HPE investigation, publication and reporting are 
summarized in Fig 3.
Mehta and Mehta Page 4













Regulatory Activities, Device Discontinuations and Device Recalls
Despite compounding challenges associated with HPE reporting, documentation of adverse 
events continues to influence global trends in vascular device manufacturing, regulation and 
clinical practices (Fig. 1). Following initial case descriptions by Barnwell et al. in 1997, the 
Fastracker-18 microcatheter was discontinued by the manufacturer (Target Therapeutics, 
Fremont, Calif) [2]. Following recognition of localized access site complications by Kozak 
et al. in 2003, warning labels were instituted on specific branded vascular sheaths (Cook 
Inc., Bloomington, IN) [13]. Following reports of morbidity and mortality associated with 
distal embolism from multiple device types in 2008-2010 [3,4,8,9], FDA guidance 
recommendations were put forth for industry and regulatory staff regarding particulate 
testing of stents, delivery systems and percutaneous transluminal coronary angioplasty 
(PTCA) catheters [41]. In 2010, International Standard ISO 10993-13 was revised, providing 
general requirements for preclinical simulated use testing of polymeric medical devices [42]. 
An FDA communication entitled “Critical to Quality (CtQ) Indicators: Hydrophilic Coated 
and Hydrophobic Coated Vascular and Neurological Devices” was drafted to manufacturers 
in 2015, summarizing coated device features that may be pertinent to device safety [45]. 
Following publication of postmortem HPE frequencies in 2015 [5,33], the FDA increased 
surveillance by retrospectively reviewing medical literature, medical device reports (MDRs), 
device labeling and recalls, and by actively soliciting information from physicians, engineers 
and manufacturers [7,46,47]. FDA investigation revealed almost 500 MDRs, 9 mortalities 
and multiple device recalls due to HPE. An FDA Safety Communication entitled 
“Lubricious coating separation from intravascular medical devices” was issued in 
November, 2015, alerting treating and diagnostic physicians on potential hazards and risks 
of polymer coatings and providing recommendations for safe clinical practices [46]. In all, 
16 coated intravascular medical devices were recalled by the FDA between 2010 and 2016, 
due to separation of lubricious coating materials. These included various branded 
guidewires, sheaths, retrieval devices and embolization device delivery wires (see 
Supplementary Information, Class 1 Medical Device Recalls).
Clearance Standards for Coated Intravascular Medical Technologies
To date, premarket evaluation requirements for coated vascular medical devices incorporate 
studies of coating durability and friction, with recommendations put forth for inspection of 
integrity of device surface coatings. While regulatory attention to intravascular device 
coating quality and integrity has heightened over recent years, device-specific clinical 
performance and safety data remain unavailable to hospitals, device users and patients who 
consent and undergo intravascular medical procedures. Furthermore, current standards do 
not strictly define allowable size thresholds, nor overall permissible limits for particulates 
generated during in vitro testing of coated vascular medical technologies. Section 6 of the 
AAMI TIR 42 states “because of the absence of comprehensive and definitive clinical data, 
particle size ranges and particle count limits are not recommended in this TIR” [41]. The 
International Organization for Standardization 10993 Standard Series (ISO10993), entitled 
“Biological evaluation of medical devices”, puts forth guidelines for preclearance evaluation 
of hydrophilic vascular medical device biocompatibility and safety, incorporating 
requirements for preclinical testing of device-induced cytotoxicities, immunotoxicities, 
hemocompatibility, and polymeric degradation, among other factors [42]. Part 13 of the 
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Standard, entitled “Identification and quantification of degradation products from polymeric 
medical devices”, provides general requirements for evaluating particulates released from 
polymeric medical device surfaces, when subjected to simulated clinical environments. 
Notably, recommended studies are performed by individual manufacturers via 
nonstandardized protocols [41]. Applicants most often provide FDA with evidence that new 
devices are “substantially equivalent” to devices already on the market (i.e., predicate 
devices). Devices can then be cleared by 510(k) processes, which do not require any clinical 
testing prior to formal product release. Thus, analyses of the distal vasculature, organ-
associated responses and/or long-term biological polymer effects in living systems are not 
specifically evaluated, and to date their effects remain unknown. Furthermore, standardized 
methodologies for in vivo device testing are currently unspecified [42].
Need for Additional Premarket and Postmarket Oversight and Device Monitoring
While recommendations outlined in AAMI TIR 42 [41] suggest that manufacturers 
introducing new devices should obtain comparative data on particulate matter from predicate 
devices, the safety and efficacy of predicate devices are unproven. Furthermore, clinical 
evidence shows that established pre-clinical simulated use testing is not fully predictive of 
device coating performances in real-world settings [2-46]. Current ISO10993 standards do 
not specify in vivo testing procedures for degradable polymeric devices, including screening 
of device surface changes upon animal or human blood contact, analyses of vessel-device 
interface reactions, determination of degree, quality and/or rates of intravascular coating 
biodegradation and particulate release, or analyses of biological implications of polymer 
deposits within distal vasculature and end-organs [5,6,42]. Additional experimental and 
clinical testing and device analyses are therefore needed. Coordinated efforts in this area 
would allow for more accurate, comprehensive and integrated device evaluation and 
surveillance, while promoting more timely, reliable and direct feedback regarding patient 
risks and device performances to patients, physicians, manufacturers, additional industry 
personnel and the FDA (Fig. 4).
Etiologies for Polymer Abrasion - Mechanical Factors and Need for Additional In Vitro 
Device Testing
Mechanical factors that may influence polymer coating delamination from vascular device 
surfaces include excess friction, such as with coated device use in tortuous, atherosclerotic, 
narrowed and/or attenuated vessels [40,43]. Passage of devices across acutely angulated 
bifurcation sites, manipulation of tight-fitting device combinations, coaxial techniques 
involving curved, irregular, stiff or sharp edged devices, and multiple difficult attempts at 
vascular cannulation [40,45] likely further contribute to surface disruption. Operator skill, 
specific device types, coating compositions, intrinsic base coat bonding properties, curing 
processes, and device coverage styles such as complete versus partial device coverage, 
submicron (thin) versus micron (thick) coats and device surface substrate modification have 
additionally been shown to influence incidences of mechanical polymer peeling and flaking 
from device surfaces [7,33,48,49]. Frequency of intravascular procedures and devices used, 
improper handling or use of devices including incorrect sizing or reshaping, and use of 
damaged or expired devices likely additionally predispose to mechanical disruption and 
coating abrasion. Expanded, systematic in vitro device testing is therefore needed to assess 
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contributory chemical, manufacturing, storage, operator and patient-related factors that 
predispose to mechanical coating disruption and delamination.
Etiologies for Polymer Biodegradation – Hydration and Biological Factors and Need for 
Additional In Vivo and Ex Vivo Device Testing
Surface biomaterials may be further compromised due to dissolution in solutions and/or air. 
Degradation during product development, storage and use would be expected to vary with 
polymer bonding and composition(s), and in many cases would be critically time-dependent. 
Variable rates of bond breakage would be expected to occur upon subjection of devices to 
different aqueous and/or biological conditions [6,10,40]. Evaluation of device surface 
qualities and degradative time courses along various stages of product lifecycle is therefore 
warranted to allow for better understanding of safety, coating integrity, and particulate 
release. Coating degradation may result from improper or suboptimal device processing 
(e.g., heat versus ultraviolet curing or light exposure), packaging and storage (e.g., sustained 
or suboptimal temperatures or humidity), sterilization method (e.g., autoclaving, 
irradiatiation or use of ethylene oxide), and preparation (e.g., prolonged hydration and/or use 
of incorrect solutions). Moreover, rapid biodegradation may be associated with prolonged 
blood contact, extended procedural times, and baseline patient conditions. In light of diverse 
clinical scenarios and complexities of device manufacturing, storage, preparation and use, 
investigation of device-specific biodegradation and vascular reaction patterns under 
controlled clinical environments, incorporating real-world conditions in distinct patient 
subsets, and under different environmental conditions of manufacturing, sterilization, 
storage, and use would be highly relevant [5,6,42,50]. Expanded in vivo and ex vivo device 
testing for investigation of surface integrity and measures of particulate release is needed to 
provide safety data regarding individual device use and potential for long-term biological 
effects [6,7,10].
Unique Considerations of HPE in Distinct Patient Subsets
Risks associated with HPE phenomena likely further vary in distinct patients, due to unique 
anatomical and clinical considerations. As friction resulting from device–vessel and device–
device contact may be a primary etiological factor predisposing to surface shearing, 
attenuated vessel caliber and incorrect device sizing may introduce distinct risks within the 
infant, pediatric, adolescent, and adult female and male populations. Structural cardiac 
abnormalities and presence of right-to-left cardiac shunts would predispose to 
cerebrovascular and systemic embolic events. Immature infant and pediatric organs would 
be more susceptible to multifocal foreign body deposition and inflammatory and 
developmental sequelae. Cumulative subclinical responses would likely result in additive 
complications over the course of a lifetime in patients who are younger and undergo 
repeated endovascular procedures or harbor chronic indwelling catheters or implanted 
devices. Furthermore, embolic events are more likely to be symptomatic among patients 
with compromised baseline vascular reserve or comorbid disease including acidosis, 
immunosuppression, hyperinflammation, or potential toxicological or pharmacological 
interactions. Given potential diverse clinical effects, optimal coating applications and 
thicknesses may be investigated in patient subsets to determine permissible thresholds in 
distinct organ systems and populations treated. In particular, safety standards may be more 
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stringently imposed with regard to pediatric devices, due to potential for long term effects 
and unique size considerations with propensity for vasoocclusion in distal small vessels and 
developing organs.
Overall Implications for Manufacturing, Regulation and Device Surveillance
A review on HPE raises several red flags and highlights inefficiencies in multiple systems, 
both within the United States and internationally. The HPE issue was overlooked and 
perpetuated due to cumulative flaws and gaps in existing systems for medical peer-review, 
medical device clearance, medical device surveillance and facility auditing (Fig 3). An 
exhaustive 2011 Institute of Medicine (IOM) analysis, conducted at the request of the FDA, 
concluded that the 510(k) process for medical device clearance is intrinsically flawed and 
suggested that the device approval system in the United States should be replaced [51]. The 
current review illustrates specific failures of the 510(k) process as well as MDR-based 
postmarket surveillance processes in regard to identifying and addressing critical adverse 
device events and emerging trends [52].
Notably, since physicians are not specifically required to investigate or report adverse device 
events, underreporting persists as a major impediment of current voluntary reporting 
systems. Although facilities are required to report detected adverse events, no specific 
penalties are imposed for not reporting. Inefficiencies of voluntary facility reporting systems 
were documented in a 2010 Office of Inspector General (OIG) Report which found that 
incident reports were not generated for 93% of events in hospitals surveyed [53]. Moreover, 
as stated in a 2016 Duke-Margolis Center for Health Policy Report, weakness in the current 
postmarket surveillance system “significantly affects public health and biomedical 
innovation, by creating obstacles for patients and clinicians to receive the meaningful 
information they need to make informed decisions, perpetuating unnecessarily long delays 
and gaps in effective and timely safety communications and recall management, hindering 
the timely development of new and innovative treatment options, and increasing the overall 
costs and inefficiency of the health care system.” [54].
The 2015 FDA Safety Communication on lubricious device coatings acknowledged rising 
concerns and gaps in national and international standards for coated vascular devices and 
stated that the agency would work with stakeholders to develop nonclinical test 
methodologies and establish device performance criteria to address these gaps [46]. In 2016, 
the FDA awarded the Medical Device Innovation Consortium (MDIC), a 501(c)(3) public-
private partnership created for the purpose of advancing pre- and post-market investigations 
into safety of medical devices, with $3 million in seed funding to establish a Coordinating 
Center for the National Evaluation System for health technology (NESTcc). Stated 
organizational goals of NESTcc include introducing patient-centered approaches to medical 
device surveillance, increasing cost-effective use of real-world evidence (RWE) across total 
product lifecycles (TPLC), promoting projects to facilitate evidence generation and data 
sharing, and engaging various stakeholders across medical device ecosystems through 
outreach and educational activities. To date, however, a concrete plan for corrective action to 
the HPE issue has not materialized.
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Next Steps and Need for Device Registries for Further Clinical HPE Characterization
Assurances of medical device safety are a collective responsibility and benefit all system 
members – patients, healthcare payers and providers, manufacturers, and the FDA. Each 
party has a distinct role in promoting the wellbeing of patients, and without interdisciplinary 
discussion and sharing of information, progress on medical device safety issues cannot occur 
[55-58]. The assembly of consortia amenable to more open communication and more 
proactive and innovative investigative approaches for device performance and safety testing 
is needed. To more efficiently assess product designs, histopathological HPE evidence and 
epidemiological data, development of standardized testing methods for vascular devices 
would be required, along with formal partnerships between regulators, manufacturers, and 
treating and diagnostic physicians. Formal, large-scale device databases and centralized 
tissue registries should be developed to allow for systematic reporting and facilitate 
investigation of device events. While the need for an infrastructure for institution of national 
device-specific registries has been acknowledged by the FDA [59], it remains unclear how 
this would be implemented in regard to investigation of coated vascular medical 
technologies, who would be responsible for supporting and funding these initiatives, and 
how non-biased physicians and researchers with interdisciplinary expertise and knowledge 
would be incorporated into an appropriate system of oversight.
The current manuscript summarizes histopathological evidence regarding in vivo HPE 
reactions that could be further analyzed and incorporated as end-points for systematic 
postmarket device surveillance. Available information regarding diagnostic imaging and 
laboratory findings have been summarized [5,6,40]. Continued and expanded work on this 
subject should include determination of optimal methods to quantitate polymer particulate 
release, both in vitro and in vivo, and to systematically evaluate secondary HPE reactions in 
living systems. Standardized testing would help bring public safety information regarding 
device-specific and coating-specific performances [6,49,60]. A universal, sensitive and 
specific testing method for measuring coating particulates from vascular medical devices, 
however, will not be feasible. Rather, a battery of relevant screening and testing methods 
would be needed to accurately capture qualities and rates of particulates generated under 
various environmental and biological conditions, and at various stages of product lifecycles. 
Given the complexity and diversity of intravascular device types, available coating 
compositions, applications and curing processes, etiologies for delamination, 
clinicopathological HPE effects, and underlying patient comorbidities, large-scale 
investigations are needed to allow for more meaningful and comprehensive analyses. Until 
causes and effects of coating particulates are better understood, and until definitive standards 
can be determined, research in humans and experimental models would be beneficial to 
increase knowledge on appropriate testing methods and considerations for patient safety.
Priority areas for future investigation should include further characterization of intermediate- 
and long-term biological responses of distinct polymeric agents within the human 
bloodstream, elucidation of temporally heterogeneous organ-specific iatrogenic effects, and 
determination of time-dependent coating degradation as pertains to usage and distinct device 
designs. Likewise, understanding and stratifying the clinical effects of various particulate 
compositions, and effects of particulate sizes and burdens in distinct organs and vascular 
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territories will be required to establish acceptable thresholds and permissible polymer 
particulate limits. New standards would likely be distinct for different coating types (e.g., 
synthetic versus natural materials), vascular territories instrumented (e.g., intracerebral 
versus intracardiac, peripheral vascular, or other site), intended use and duration (e.g., 1 hour 
versus 1 day, 1 month, or beyond), and population treated. Elucidation of the role of patient 
age, gender, comorbidities and concomitant pharmacotherapies in pathogenesis, metabolism 
and excretion of HPE, would be critical for bringing increased knowledge to help optimize 
device technologies and facilitate better device selections for future patients [6,46,60].
Conclusions
While lubricious polymers have distinct advantages for application as vascular medical 
device coatings, detection of adverse clinical events attributed to their use have steadily 
increased over the past decade, coinciding with increasing coated device use and 
complexities of endovascular procedures and technologies. Moreover, HPE effects have 
proven to be complex and highly variable, depending on particulate sizes and load, coating 
and device compositions and designs, temporal related factors and various patient 
comorbidities. These complexities suggest a need for updated approaches to testing and 
monitoring clinical benefits and risks of existing and new devices. Increased attention to 
device-specific polymer particulate release and coating performances should be a priority 
area for future medical research, manufacturing and regulation. Given the nature of 
biomaterial coatings and potential risks, safety testing for newly introduced coated 
intravascular medical device types should incorporate systematic tissue-based and/or clinical 
monitoring to allow for risk assessment in real-world settings. Novel materials, device 
surface substrate modifications, and/or alternative coating methodologies should be 
investigated to further optimize safety and efficacy of future devices.
In regard to general device safety testing and investigation, the FDA has cited a lack of 
financial support for programmatic change. Analyses of the postmarket surveillance system 
by the Brookings Institution stated that increased congressional support, FDA engagement 
and appropriations are needed to create and sustain the appropriate infrastructure and public-
private partnerships necessary for a robust and effective medical device surveillance system 
in the United States [54]. Our experience and independent analyses reveal that lack of 
incentivization and dedicated support for physician investigators is a primary hindrance to 
timely investigation and progress in the field. Thus, comprehensive work on this subject 
would depend on development of an appropriate infrastructure and identification of funding 
sources for collaborative investigation on vascular medical device coatings and associated 
risks. Despite challenges in this area, the significant global public health relevance warrants 
increased attention to enhance patient safety and help bring critical system and device 
improvements.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Timeline and Evolution of Coated Intravascular Medical Device Technologies
The published clinical literature (1986-2016), highlights a gradual increase in HPE reporting 
over the course of three decades, with increasing recognition of implications for public 
health and safety.
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Figure 2. HPE Formation and Heterogeneous Histologic Appearances
(A) Depiction of polymer delamination from a vascular medical device surface, with 
localized access site deposition (black arrow) and embolic phenomena (white arrow); (B) 
Histologic features include basophilic, granular, coiled intravascular foreign bodies, with 
associated giant cells and granulomata (single arrow) and/or neutrophilic response (double 
arrows); gradual intravascular degradation may result in progressive eosinophilic change 
(i.e., pink coloration), as seen from left to right; (C) Low-power scanning microscopy may 
reveal heterogeneous degradation of HPE (arrows), with mimicry of native tissues; (D) 
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High-power images (boxed areas in C) demonstrate variable light microscopic appearances; 
(B-D) Hematoxylin and eosin stain; (B) 400X; (C) 40X; (D) 1000X (oil immersion).
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Figure 3. Postmarket HPE Surveillance: Current Hazard Barriers, System Members and System 
Failures
Historically, medical device reports (MDRs) have been used for primary device surveillance. 
MDRs submitted through MedWatch are entered into the Manufacturer and User Facility 
Device Event (MAUDE) database and are monitored by the Office of Suveillance and 
Biometrics (OSB) to identify device problems and determine trends. Abbreviations: FDA, 
Food and Drug Administration; QA, quality assurance; QC quality control. *Multifactorial, 
beyond the scope of the current manuscript
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Figure 4. Proposed Changes for Device Particulate Evaluation and Testing
Ideally, testing for coating particulates and device safety should occur at different stages of 
product lifecycles, during manufacturing, approval, and postmarket use, to assess for quality 
and risks of coating delamination in variable real-world settings.
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Table 1
Documented HPE Cases: Published Clinical Reports and Author Consult Data, with Patient Numbers.
Year Authors Tissue or Organ(s) Affected (Number of 
Patients)
Access Site vs. Distal Embolic 
Event
Reference
1997 Barnwell SL et al.2 Brain (4) Distal 2
2003 Kozak M et al.13 Skin (10) Access Site 13
2003 Subramanian R et al.12 Skin (1) Access Site 12
2005 Ziakas A et al.14 Skin (1) Access Site 14
2008 Fealey ME et al.3 Brain (1) Access Site 3
Skin (2) Distal
2009 Mehta RI et al.8 Brain (1) Distal 8
2009 Allen RW et al.4 Lung (1) Distal 4
2010 Mehta RI et al.9 Brain (2) Distal 9
Lung (5)
Skin (1)
2012 El-Najjar V et al.19 Heart (1) Distal 19
2012 Schipper ME et al.20 Heart (1) Distal 20
2013 Sequeira A et al.21 Heart (1) Distal 21
Kidney (1)
Arteriovenous graft (1)
2014 Hu YC et al.22 Brain (3) Distal 22
2014 Sanon S et al.24 Heart (1) Distal 24
2014 Rosen LE et al.27 Heart (1) Distal 27
2014 Danowski KM et al.25 Skin (1) Distal 25
2014 Hamidi S et al.26 Skin (1) Distal 26
2015 Mehta RI et al.5 Lung (18) Distal 5
Brain (1)
Heart (1)
2015 Hardy CL et al.32 Skin (1) Distal 32
2015 Chen CL et al.23 Kidney (1) Distal 23
2015 Thompson AK et al.31 Skin (8) Distal 31
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Year Authors Tissue or Organ(s) Affected (Number of 
Patients)
Access Site vs. Distal Embolic 
Event
Reference
2015 Shapiro M et al.30 Brain (2) Distal 30
2015 Fujisaka T et al.29 Heart (1) Distal 29
2015 Grundeken MK et al.33 Heart (4) Distal 33
2016 Mehta RI et al.15 Brain (6) Distal 40
2016 Goto K et al.37 Skin (1) Distal 37
2016 Chavez JA et al.35 Colon (2) Distal 35
Aorta (1)
2016 Lorentzen AO et al.38 Brain (1) Distal 38
2016 Rapkiewicz A et al.28 Lung (1) Distal 28
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Table 2







Potential Acute Events Potential Subacute or Delayed Events








Tissue or Spinal Cord
590 μm 1.5 cm Focal neurological deficits Focal neurological deficits
Coma/mental status change Meningismus/headache
Meningismus/headache Coma/mental status change
Hemorrhagic stroke Cerebral vasculitis
Ischemic stroke Cerebral granulomas
Death Cerebral abscesses
Cerebral thrombosis






Heart 530 μm Arrhythmia Arrhythmia
Cardiac thrombosis Cardiac thrombosis
Myocardial hemorrhage Cardiac granulomas




Kidney 520 μm 1.0 cm Acute renal failure Oliguric renal failure
Renal abscesses
Hematuria




Colon 400 μm Acute gastrointestinal hemorrhage Ischemic colitis


























Arteriovenous Graft 340 μm Acute graft hemorrhage Chronic graft arteritis
Graft thrombosis
Delayed graft hemorrhage











Spleen 200 μm Subcapsular hemorrhage Splenic granulomas
Muscle 180 μm Intramuscular hemorrhage Muscle granulomata
Patchy myositis
Adrenal Gland 100 μm Adrenal cortical hemorrhage Focal adrenal microhemorrhage
Systemic Effects Variable Variable Multifocal hemorrhage Multifocal vasculitis
Constitutional Symptoms (Fever, 





Multifocal thrombosis and hemorrhage
Disseminated intravascular coagulation
Systemic inflammatory response syndrome
Death
*
Indicates greatest detected cross-sectional (C.S.) or longitudinal (L.) HPE dimension, where identifiable or reported. Findings were confirmed on 
diagnostic light microscopy and/or extrapolated by a pathologist based on submitted light microscopic data.
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Table 3
Primary System Failures and Potential Improvements for Enhanced Device Quality and Safety
Primary System Failures Potential Quality and System Improvements
Lack of Defined Regulatory Standards
➢Absence of systematic in vivo particulate testing 
(i.e., animal model and/or clinical evaluation)
Disincentives and Lack of Incentives for Investigating 
and Reporting on Device Events
➢Lack of support, resources, time and funding for 
research and postmarket surveillance initiatives
➢Liability issues for hospitals and treating physicians
Lack of Communication/Miscommunications Among 
Physicians and System Members
➢Lack of transparency and feedback
Over-Reliance on Medical Device Reports (MDRs) as a 
Primary Postmarket Surveillance Tool
➢Limitations on utility and timeliness of passive 
device reporting and nonintegrated surveillance 
methods
Conflicts of Interest Among Stakeholders
➢Inherent biases of manufacturers and device users
Resistance to Challenging Established Guidelines
➢Impediments in declaring unexpected new findings
Delays in Disseminating Postmarket Findings
➢Publication delays and gaps in physician alerting
Update Regulatory Standards and Safety Requirements for 
Coated Vascular Devices
➢Conduct systematic, prospective device-specific testing for 
in vivo particulate release, to assess coating integrity and 
end-organ effects in animal models and/or patient subsets
Strengthen Postmarket Surveillance Initiatives
➢Reimburse for select medical autopsies and quality and 
safety improvement initiatives; allocate funding and 
institutional support for research and event reporting
Support Individual Physicians and Investigators
➢Flag potential hazards for expanded investigation
➢Encourage investigation of novel hypotheses
Foster Team-Based Investigational Approaches
➢Encourage joint prospective initiatives between diagnostic 
physicians-treating physicians-regulators-manufacturers
➢Pool multi-institutional post-procedural outcome data
➢Create regional and national clinical databases
➢Create centralized tissue and device registries
Mitigate Biases and Conflicts of Interest
➢Advocate for non-biased investigation and reporting
Facilitate Public Availability of Postmarket Data
➢Disclose cytotoxicity/immunotoxicity and particulate 
release data regarding individual proprietary coatings and 
devices
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